| 02/02 | Cullinan Oncology to Participate in the Guggenheim 5th Annual Oncology Conference and t.. | GL |
| 02/02 | Cullinan Oncology to Participate in the Guggenheim 5th Annual Oncology Conference and t.. | GL |
| 02/01 | Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | GL |
| 01/24 | Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application .. | GL |
| 01/24 | Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application .. | AQ |
| 01/19 | Cullinan Oncology, Inc. : Unregistered Sale of Equity Securities, Amendments to Articles o.. | AQ |
| 01/06 | Cullinan Oncology : Corporate Presentation January 2023 | PU |
| 01/03 | Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | GL |
| 2022 | Cullinan Oncology : Corporate Presentation December 2022 | PU |
| 2022 | Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | GL |
| 2022 | Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | AQ |
| 2022 | CULLINAN ONCOLOGY, INC. Management's Discussion and Analysis of Financial Condition an.. | AQ |
| 2022 | Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2022 Financial Re.. | GL |
| 2022 | Cullinan Oncology, Inc. : Change in Directors or Principal Officers, Financial Statements .. | AQ |
| 2022 | Cullinan Oncology Announces the Appointment of David P. Ryan, M.D. to its Board of Dire.. | GL |
| 2022 | Cullinan Oncology Announces the Appointment of David P. Ryan, M.D. to its Board of Dire.. | AQ |
| 2022 | Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | GL |
| 2022 | Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | GL |
| 2022 | Cullinan Oncology to Participate in Upcoming Investor Conferences | GL |
| 2022 | Cullinan Oncology, Inc. : Entry into a Material Definitive Agreement, Regulation FD Disclo.. | AQ |
| 2022 | Cullinan Oncology Significantly Increases Ownership Stake in its MICA Subsidiary which .. | GL |
| 2022 | Cullinan Oncology Significantly Increases Ownership Stake in its MICA Subsidiary which .. | AQ |
| 2022 | Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | GL |
| 2022 | Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | AQ |
| 2022 | Cullinan Oncology to Participate in the HC Wainwright Global Investment Conference and .. | GL |
| 2022 | Cullinan Oncology to Participate in the HC Wainwright Global Investment Conference and .. | AQ |
| 2022 | Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | GL |
| 2022 | Cullinan Oncology Announces Appointment of Jacquelyn Sumer as Chief Legal Officer | GL |
| 2022 | Cullinan Oncology Announces Appointment of Jacquelyn Sumer as Chief Legal Officer | GL |
| 2022 | Cullinan Oncology : Provides Corporate Update and Reports Second Quarter 2022 Financial Re.. | PU |
| 2022 | CULLINAN ONCOLOGY, INC. Management's Discussion and Analysis of Financial Condition an.. | AQ |
| 2022 | Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2022 Financial R.. | GL |
| 2022 | Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | GL |
| 2022 | Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | AQ |
| 2022 | Cullinan Oncology to Participate in BTIG Biotechnology Conference and Canaccord Growth .. | GL |
| 2022 | Cullinan Oncology to Participate in BTIG Biotechnology Conference and Canaccord Growth .. | AQ |
| 2022 | Cullinan Oncology to Participate in William Blair Biotech Focus Conference | GL |
| 2022 | Cullinan Oncology to Participate in William Blair Biotech Focus Conference | AQ |
| 2022 | Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | GL |
| 2022 | Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | GL |
| 2022 | Cullinan Oncology : UNAUDITED PRO FORMA FINANCIAL INFORMATION - Form 8-K | PU |
| 2022 | Cullinan Oncology, Inc. : Completion of Acquisition or Disposition of Assets, Regulation F.. | AQ |
| 2022 | Cullinan Oncology, Inc. : Submission of Matters to a Vote of Security Holders (form 8-K) | AQ |
| 2022 | Cullinan Oncology and Taiho Pharmaceutical Complete Agreement for Strategic Collaborati.. | GL |
| 2022 | Cullinan Oncology and Taiho Pharmaceutical Complete Agreement for Strategic Collaborati.. | GL |
| 2022 | Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | GL |
| 2022 | Cullinan Oncology to Present Updated Data Demonstrating the Therapeutic Potential of CL.. | GL |
| 2022 | Cullinan Oncology to Present Updated Data Demonstrating the Therapeutic Potential of CL.. | AQ |
| 2022 | Cullinan Oncology to Host Analyst and Investor Briefing at 2022 ASCO Annual Meeting | GL |
| 2022 | Cullinan Oncology to Present at H.C. Wainwright Global Investment Conference | GL |
| 2022 | Cullinan Oncology to Present at H.C. Wainwright Global Investment Conference | AQ |
| 2022 | CULLINAN ONCOLOGY, INC. Management's Discussion and Analysis of Financial Condition an.. | AQ |
| 2022 | Cullinan Oncology Provides Corporate Update and Reports First Quarter 2022 Financial Re.. | GL |
| 2022 | Cullinan Oncology Provides Corporate Update and Reports First Quarter 2022 Financial Re.. | AQ |
| 2022 | Cullinan Oncology, Inc. : Entry into a Material Definitive Agreement, Results of Operation.. | AQ |
| 2022 | Cullinan Oncology and Taiho Pharmaceutical Announce Strategic Collaboration to Jointly .. | GL |
| 2022 | Cullinan Oncology and Taiho Pharmaceutical Announce Strategic Collaboration to Jointly .. | AQ |
| 2022 | Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | GL |
| 2022 | Cullinan Oncology to Present Updated Data Highlighting the Therapeutic Potential of CLN.. | AQ |
| 2022 | Cullinan Oncology to Participate in Upcoming Virtual Healthcare Conferences | AQ |
| 2022 | Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | GL |
| 2022 | Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | GL |
| 2022 | Cullinan Oncology Announces Clinical and Regulatory Update for CLN-081 in NSCLC EGFR Ex.. | AQ |
| 2022 | CULLINAN ONCOLOGY, INC. Management's Discussion and Analysis of Financial Condition an.. | AQ |
| 2022 | Cullinan Oncology : Provides Corporate Update and Reports Fourth Quarter and Full Year 202.. | PU |
| 2022 | Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 20.. | GL |
| 2022 | Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 20.. | GL |
| 2022 | Cullinan Oncology to Host CLN-081 Regulatory Update Webinar on March 28, 2022 | AQ |
| 2022 | Cullinan Oncology to Present at the Barclays Global Healthcare Conference | AQ |
| 2022 | Cullinan Oncology to Present Data Demonstrating Breadth and Progress of Its Immuno-Onco.. | GL |
| 2022 | Cullinan Oncology, Inc. : Change in Directors or Principal Officers, Financial Statements .. | AQ |
| 2022 | Cullinan Oncology Expands Leadership Team and Board of Directors with Appointments of J.. | AQ |
| 2022 | Cullinan Oncology to Present at SVB Leerink's 11th Annual Global Healthcare Conference | AQ |
| 2022 | Cullinan Oncology Forms Strategic Collaboration Agreement with Mount Sinai to Advance O.. | GL |
| 2022 | Cullinan Oncology to Present at Upcoming Virtual Investor Conferences | AQ |
Google
Twitter
Facebook
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
